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Background: Hepatitis C virus (HCV) is a common and leading cause for liver cirrhosis and hepatocellular carcinoma.
Current therapies to treat HCV infection are shown to be partially effective and poorly tolerated. Therefore, ample
efforts are underway to rationally design therapies targeting the HCV non-structural proteins. Most of the work carried
out in this direction has been focusing mainly on HCV genotype 1. Two direct-acting antiviral agents (DAAs) Telaprevir
and Boceprevir are being used against genotype 1a infection in combination therapy with interferon and ribavirin.
Unfortunately these DAAs are not effective against genotype 3a. Considering the wide spread infection by HCV
genotype 3a in developing countries especially South Asia, we have focused on the recombinant production
of antiviral drug targets NS3 and NS5A from HCV genotype 3a. These protein targets are to be used for screening
of inhibitors.
Results: High-level expression of NS3 and NS5A was achieved at 25°C, using ~1 and 0.5 mM Isopropyl
β-D-1-thiogalactopyranoside (IPTG), respectively. Yields of the purified NS3 and NS5A were 4 and 1 mg per liter culture
volume, respectively. Although similar amounts of purified NS3 were obtained at 25 and 14°C, specificity constant
(Kcat/Km) was somewhat higher at expression temperature of 25°C. Circular dichroism (CD) and Fourier-transform
infrared (FT-IR) spectroscopy revealed that both NS3 and NS5A contain a mixture of alpha-helix and beta-sheet
secondary structures. For NS3 protein, percentages of secondary structures were similar to the values predicted
from homology modeling.
Conclusions: NS3 and NS5A were over-expressed and using Nickel-affinity method both proteins were purified
to ~ 95% purity. Yield of the purified NS3 obtained is four fold higher than previous reports. CD spectroscopy revealed
that difference in activity of NS3 expressed at various temperatures is not related to changes in global structural features
of the protein. Moreover, CD and FT-IR analysis showed that NS3 and NS5A contain both alpha-helical and beta-sheet
structures and for NS5A, the proportion is almost equal. The production of NS3 and NS5A in milligram quantities will
allow their characterization by biophysical and biochemical means that will help in designing new strategies to fight
against HCV infection.
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Hepatitis C Virus (HCV) was first identified in 1989
[1], however, research was initially delayed due to the
difficulty to culture the virus efficiently in vitro [2].
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reproduction in any medium, provided the orliver failure and death of the infected person [3]. Ac-
cording to an estimate of World Health Organization,
around 170 million people are infected with HCV, with
an additional 3–4 million infected every year [4]. The
risk of the prevalence of this disease is decreased with
the advent of new blood screening tests. Yet, in developing
countries, wide transmission still occur mainly by paren-
teral exposure to contaminated blood or blood products
or by the illicit use of injectable drugs [5].
HCV belongs to genus hepacivirus of family Flaviviridae
and is an enveloped positive stranded RNA virus [6]. ItLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protein of 3000 amino acids which is further cleaved into
10 proteins by host signal peptidases and viral proteases
[7,8]. Coding sequences for first 3 structural proteins
reside in the 5′ region of HCV genome including the core
(C), and two envelope glycoproteins (E1 and E2). The
structural proteins play a major role in the encapsulation
of the virus. C, E1 and E2 genes are followed by p7 gene
whose product is considered to work as an ion channel
and its maturation is catalyzed by endogenous peptidases.
Coding regions of six non-structural proteins (NS2, NS3,
NS4A, NS4B, NS5A and NS5B) are present at 3′ end of
HCV genome. Non-structural proteins are mainly involved
in process of replication and maturation of HCV [9].
In spite of the intensive research on HCV, it continues
to pose a major threat to the developing world. The only
treatment available for HCV is pegylated interferon alone
or in combination with ribavirin for 24 to 48 weeks
based on the genotype of virus. Response of genotype 1
to current treatment is 42 to 46% whereas genotypes 2/
3 responds to 76 to 80% [10]. This antiviral therapy is
expensive, has considerable side effects and in some
cases is not effective beyond the period of treatment. A
number of DAAs are in clinical phase 1, 2 and 3 trials
that are designed against specific protein targets (NS3,
NS5A and NS5B) which are essential to the life cycle of
the virus [11-13]. Two DAAs Telaprevir and Boceprevir
have been approved by FDA in 2011. These DAAs are
used in combination therapy with interferon and ribavirin
to combat infections caused by HCV genotype 1a [14].
NS3 and NS5B are considered to be the main targets of
this regime because they can be directly used for inhibitors
screening due to their enzymatic properties [15]. NS3
consists of 631 amino acids (aa), out of which N-terminal
180 aa form a protease domain while remaining consti-
tutes helicase/ATPase part of the protein. The protease
domain plays an important role in the processing of
HCV polyprotein using the NS4A as a cofactor [16].
NS4A not only plays an important role in the activation
of NS3 protease, it also anchors NS3 to membrane of
endoplasmic reticulum during process of replication
[17]. Helicase domain of NS3 activates the separation
of double stranded RNA using ATP as an energy source
[18]. Moreover, NS3 also interferes the host immune
system by targeting the host proteins such as TRIF and
MAVS that act as signaling adapter for toll like receptor 3
and mitochondrial antiviral signaling protein, respectively
[16]. Although Protease and helicase domains of NS3
can work independently, cofactor NS4A is required for
efficient functioning of NS3 protease [19].
NS5A performs critical role in the virus persistence
and pathogenesis. Its interaction with a large number of
host and viral proteins during replication and assembly
of virus, makes this protein an important antiviral drugtarget [20,21]. NS5A also has significant role in the
process of lipid accumulation that finally leads to stea-
tosis [22,23]. Work on the discovery of NS5A′ inhibitors
is continuing and so far only one inhibitor “Daclatasvir” is
available that is in phase 3 clinical trials [13,24]. Dacla-
tasvir is effective for treatment of infection caused by
HCV genotype 1a. NS5A consists of 3 domains; domain
I and domain II are essential for viral replication whereas
domain III plays a key role in virion assembly [25,26]. The
crystal structure of domain 1 has been solved, suggesting
that NS5A forms a dimer that contains a groove for
binding RNA at the interface between the monomers [27].
The prevalence of HCV in Pakistan/South Asia is on
the rise, currently at approximately 10% [28]. The most
prevalent genotype in this region is 3a [29]. Inhibitors
such as Telaprevir, Boceprevir and TMC435 targeting NS3
are only effective against HCV genotype 1. MK-5172,
another inhibitor of NS3, which is supposed to be
effective against all genotypes, is still in clinical trials
[30]. Research is progressing to exploit the potential of
NS5A as an antiviral target [31].
First step towards designing effective inhibitors is to
obtain sufficient quantities of the target protein. Such
quantities will enable extensive functional and structural
analyses required for the rational design of inhibitors.
To our knowledge there is no systematic study has been
performed to over-express and purify NS3 and NS5A of
HCV genotype 3a. Considering the importance of NS3
and NS5A as antiviral drug targets, we have successfully
devised over-expression and purification methods to
produce the indicated proteins in quantities sufficient
for functional and structural studies with and without
inhibitors. In addition, we have functionally and struc-
turally characterized HCV NS3 and NS5A proteins from
genotype 3a.
Results and discussion
Infections caused by HCV pose major threats to human
health. Recently launched ‘NS3’ inhibitors (Telaprevir,
Boceprevir and TMC435) for treatment of HCV genotype
are found to be ineffective against HCV patients infected
with genotype 3a, which is prevalent in several developing
countries [32]. This might be due to amino acid sequence
variability among NS3 proteins from different genotypes
(Figure 1A). In addition to NS3 as an antiviral drug target,
significant efforts are now being made to exploit the
potential of NS5A [33]. Compared to NS3 sequence
variability, the sequence of NS5A is even more variable
(30-40%) among different HCV genotypes (Figure 1B). This
fact highlights the need to synthesize and characterize
these target protein from different genotypes to combat
HCV infection worldwide [34]. As a step forward, we have
isolated HCV genotype 3 strain from blood sample of a
























Figure 1 Percentage sequence identities between NS3 [A] and NS5A [B] proteins of various genotypes of hepatitis C virus. The
phylogenetic trees and percent identity were derived from alignments of amino acid sequences of NS3 and NS5A proteins using the program
ClustalX, version 1.83. Percent identity of NS3/3a and NS5A/3a to proteins of other genotypes is indicated. The tree was drawn using the
TreeView program. [A] The phylogenetic tree includes: NS3/3a (NCBI GenBank acc. no. AFJ79449), NS3/3b (BAA08372; Amino acids 1035–1665),
NS3/2a (BAB32872.1; Amino acid 1031–1661), NS3/2b (BAB08107; Amino acid 1031–1661)), NS3/1a (AAB66324; Amino acid 1027–1657), NS3/1b
(BAC54896; Amino acid 1027–1657). [B] The phylogenetic tree includes: NS5A/3a (AFJ79451), NS5A/3b (BAA08372; Amino acid 1981–2432), NS5A/
2b (AAF59945; Amino acid 1977–2442), NS5A/2a (AAF01178; Amino acid 1977–2442), NS5A/1a (AAB66324; Amino acid 1973–2420), NS5A/1b
(AAC15725; Amino acid 1973–2419).
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NS5A proteins were amplified using the isolated cDNA as
a template. Nucleotide sequences of NS3 and NS5A were
deposited in GenBank NCBI under accession numbers
JQ676838 and JQ676840, respectively.
Strategy for the generation of NS3, NS5A and NS5A-T
expression constructs
Nucleotide sequences of NS3, NS5A (Full length; nucleo-
tides coding for 1–452 amino acids) and NS5A-T (trun-
cated; 32–452 amino acids) along with coding sequence for
His6 at the 5′, 3′ and 5′ ends, respectively, were cloned into
pET11a vector. Resultant vectors were named as pET11a-
His6-NS3, pET11a-NS5A-His6 and pET11a-NS5A-T-His6
and overall strategy is shown in Figure 2. The Integrity of
constructs was confirmed by DNA sequencing.
Expression of NS3, NS5A and NS5A-T
Initial expression of His6-NS3, NS5A-His6 and His6-
NS5A-T was conducted at 37°C using 1 mM IPTG con-
centration in E. coli strain BL21(DE3) as described in
Methods section. Truncated version of NS5A-T (32–452
amino acids) was also tested to evaluate the effect of
N-terminal domain of 31-amino acids (which contains
an amphipathic helix that serves as a membrane anchor)
on protein expression [35,36]. Significant expression levels
of His6-NS3 and His6-NS5A-T were obtained whereas
NS5A-His6 was expressed to low level as detected by
Coomassie blue staining of SDS-polyacrylamide gel (data
not shown). Therefore, further studies were conducted
using truncated version of NS5A.To enhance the expression level and solubility of His6-
NS3 and His6-NS5A-T/HCV genotype 3a, concentration
of inducer ‘IPTG’ was optimized [37]. Previous studies
report that expression of NS3/HCV genotype 1a/2b/3a
usually obtained at 1 mM IPTG or 0.002% L-arabinose
using pET or pBAD vector systems [38-40] whereas NS5A/
HCV genotype 1a/1b is produced using 0.2-1 mM IPTG
[21,41-43]. Various IPTG concentrations ranging from
0.1-1 mM as detailed in Methods section were employed
for expression in this study. For both proteins, expression
yielded bands migrating at ~ 68.3 and ~46.5 kDa for
His6-NS3 and His6-NS5A-T, respectively (Figure 3). A
significant proportion of proteins expressed as soluble
at all IPTG concentrations. Overall, little variation in
expression of both proteins was observed at IPTG ranging
from 0.1 to 1 mM. For further expression studies, 1 and
0.5 mM IPTG concentrations were selected for His6-NS3
and His6-NS5A-T/HCV genotype 3a.
Temperature optimization and purification of NS3
and NS5A-T
Previous studies report expression of NS3 and NS5A
from different HCV genotypes using a range of tempera-
tures. For example, expression of NS3/HCV genotype 1a/
2b/3a has been achieved at 30°C and 22°C [38-40], and
NS5A has been expressed at room temperature in most
of studies [21,41,43,44]. In this study, we systematically
investigated the affect of temperature (32°C, 25°C and
14°C) on expression and purification yield of His6-NS3
and His6-NS5A-T/HCV genotype 3a. Both proteins can
be expressed at all tested temperatures and purified by
Figure 2 Strategy and graphical representation of pET11a-based expression vectors employed in this study, illustrating the position
encoded tag sequences, key restriction sites, T7 promoter and NS3, NS5A and NS5A-T (truncated sequence).
Anwar et al. Microbial Cell Factories 2013, 12:111 Page 4 of 12
http://www.microbialcellfactories.com/content/12/1/111single step Ni-NTA affinity chromatography to ~ 95%
purity as judged by Coomassie blue staining (Figure 4).
His6-NS5A-T is further polished by gel filtration to pro-
duce homogenous and mono-disperse protein (Figure 4B,
lane 4). Higher purification yields 4.0 and 1.0 mg per
liter culture volume were obtained at both 25°C, 14°C
and 25°C for His6-NS3 and His6-NS5A-T, respectively
(Table 1). Optimized expression conditions yielded four
fold purified His6-NS3 than achieved earlier [40] whereas
His6-NS5A-T yield was somewhat similar as reported
in earlier studies for NS5A or NS5A-T/HCV genotype
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Figure 3 Expression of His6-NS3 [A] and NS5A-T-His6 [B] in E. coli stra
represent insoluble (inclusion body) and soluble fraction of lysate obtained
[B] induced with indicated concentration of IPTG. The arrows indicate the
the left shows marker proteins of known molecular mass.due to its sequence variability from NS3 sequences of
other genotypes (Figure 1A). Identity of purified NS3 and
NS5A was confirmed by peptide mass finger printing
based mass-spectrometry method. CD analyses of the
purified His6-NS3 and His6-NS5A-T produced at different
temperatures (32°C, 25°C and 14°C) revealed that both
proteins are folded polypeptides (Figure 5).
Activity measurements of NS3 produced at
different temperatures
Activity of purified His6-NS3 produced at 32°C, 25°C
and 14°C was measured using a FRET based assay asB






0mM 0.1mM 0.25mM 0.5mM 0.75mM 1mM  IPTG
in BL21(DE3) and isopropyl-β-D-thiogalactoside (IPTG). ‘I’ and ‘S’
from cultures harbouring pET11a- His6-NS3 [A] or pET11a- NS5A-T-His6
mobility of monomeric His6-NS3 [A] and NS5A-T-His6 [B]. The lane on













32°C 25°C 14°C GFA B
Figure 4 Optimization of expression of His6-NS3 [A] and NS5A-T-His6 [B] in E. coli strain BL21(DE3) at various temperatures and
purification by Nickel affinity chromatography following gel filtration in case NS5A-T-His6 [B]. SDS-polyacrylamide gels stained with
Commassie brilliant blue, showed wash fraction (lane 1), purified protein fractions eluted from Ni-NTA column using 250 mM imidazole (lane 2&3)
and purified fraction of NS5A-T-His6 by gel filtration as described in Methods section. The mobilities of marker proteins of known molecular mass
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different temperatures, exhibit similar Km value when
measured at single detergent concentration (0.1 or 0.4%
n-Octyl-β-D-glucopyranoside; OGP) (Figure 6). Using
assay buffer containing 0.1% OGP, higher Km value
(~1.3 μM) for His6-NS3 was obtained than at 0.4% OGP
(~0.3 μM). Km value in the range of 1.3 μM has been
determined before for NS3/HCV genotype 1a [38].
Maximum turnover number (Kcat) and specificity con-
stant (Kcat/Km) were found to be higher for the enzyme
expressed at 32°C at both OGP concentration used in
assay buffer (Table 2). However, taking into account the
purification yield of His6-NS3 at various temperatures,
the expression at 25°C seems to be the best to get the
largest amount of enzyme, with catalytic efficiency
sufficient for conducting assays for intensive search of
inhibitors (Table 2). Relatively higher specificity constant
(Kcat/Km) for His6-NS3, expressed at 32°C might be due
to local perturbation at around active site of the enzyme
which could be the subject of future investigations.
Although similar Km values were obtained for His6-NS3,
expressed at various temperatures, Kcat/Km constants were
different to some extent. To investigate, whether these dif-
ferences relate to changes in overall structural features of
the protein, CD analysis was performed. The CD spectra
of His6-NS3 proteins expressed at different temperatures
are almost identical in the region between 200 – 240 nm
that reflects the secondary structure propensities inTable 1 Purification yield of NS3 and NS5A-T
Protein 32°C 25°C 14°C Reported
Temperature
NS3 (mg/L)1 2.5 4.0 4.0 0.3 [38], 0.92 [40], 0.45 [39]
NS5A-T (mg/L)1 0.32 1.0 0.8 1.0 [41]
1The yield of purified proteins were measured mg/liter of culture
(expression medium).proteins (Figure 5A) [45]. Thus, it is likely that the
overall structural features in His6-NS3 expressed at
various temperatures remain intact and the cleavage
efficiency of the protein does not relate to any global
structural changes.-0.90
-0.70




Figure 5 Characterization of His6-NS3 [A] and NS5A-T-His6
[B] over-expressed at 32°C, 25°C and 14°C by circular dichroism


































































Figure 6 Concentration dependence of Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-[COO]-Ala-Ser-Lys(DABCYL)-NH2 [substrate] cleavage
by NS3 produced at various temperatures. Substrate-cleavage reactions were performed using 0.1 and 0.4% OPG as described in Methods.
Data points shown were fitted to the Michaelis-Menten equation by non-linear regression.
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There are no 3 dimensional structures available for
HCV NS3 genotype 3a or the full length NS5A of any
genotype in protein data bank. Thus, to estimate secon-
dary structure of NS3 and NS5A-T we used data from
CD and FT-IR spectroscopy which indicate that both
proteins fold into mixed secondary structure components
(Figures 5A and B; 7B and D). To provide quantitative
estimate of the alpha-helical and beta-sheet content of
NS3, the measured amide I region of the spectrum
(Figure 7A; Upper panel) could be reproduced by a fit
of eight components, dominated by those indicative of
alpha-helix and beta-sheet [46-48] (Figure 7B). Quantita-
tive analysis of the spectrum predicted the presence of ~
25% alpha-helix and ~ 34% beta-sheet structures (Table 3).
Similar ratios were obtained from CD data and the
homology model of HCV NS3 genotype 3a, built using
the x-ray crystal structure of genotype 1a counterpart,
as a template (Figure 7C; Table 3) [49,50].Table 2 Catalytic efficiency of NS3 produced at various tempe
Protein Temperature Kcat (s
-1)
NS3 (0.1% OPG) 32°C 3.17 ± 0.10
25°C 2.27 ± 0.07
14°C 1.836 ± 0.11
NS3 (0.4% OPG) 32°C 1.840 ± 0.05
25°C 1.485 ± 0.04
14°C 1.176 ± 0.03
1The yield of purified proteins were measured milligram per liter of culture (ExpressSecondary structures for NS5A, quantified by FT-IR
were found to be around ~ 29% alpha-helix and beta-sheet
each whereas CD analysis revealed ~18% alpha-helix
and ~32% beta-sheet (Table 3). This discrepancy particu-
larly in case of alpha-helix contents might be due to diffe-
rent algorithms used for analysis of CD and FT-IR data.
Conclusions
We have successfully optimized conditions for the recom-
binant expression and purification of the NS3 and NS5A
proteins from HCV genotype 3a. Yield of the purified NS3
from soluble fraction of E. coli cells lysate is 4 mg per liter
culture volume, which is the highest amount, obtained for
this genotype to the best of our knowledge. CD studies
show that difference in activities of NS3 produced at
different temperatures is not due to changes in the
overall structural features of the expressed proteins.
CD and FT-IR spectra suggest that both proteins are
folded into a mix of alpha-helix and beta-sheet secondaryratures
Kcat/Km Kcat/Km (μM
-1 · s-1)




























































































































































































































Figure 7 Analysis of His6-NS3 [A,B,C] and NS5A-T-His6 [D] secondary structure by FT-IR and homology modeling. [A] Lower panel: FT-IR
spectra of hydrated film of 10 mM phosphate buffer pH 7.4 and His6-NS3 protein. Upper panel: Final protein spectrum obtained by subtracting
the buffer spectrum. [B] Second derivative spectrum of His6-NS3 and amide I region of the FTIR spectrum of a hydrated film of His6-NS3 (thick
grey line), and bands obtained by deconvolution. The dotted red line shows the curve fitted using the component bands. [C] Homology model
of NS3/3a, built using the x-ray structure of NS3/1a as a template (PDB id: 3o8b). The protease and helicase domains are shown in red and green
respectively. [D] Second derivative spectrum of NS5A-T-His6 and amide I region of the FT-IR spectrum of a hydrated film of NS5A-T-His6 (thick
grey line), and bands obtained by deconvolution. The dotted red line shows the curve fitted using the component bands. The peak position of
the spectral components along with their assignment is shown in the figure.
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quantities of purified NS3 and NS5A is expected to allow
rigorous biochemical and biophysical characterization,
and screening of inhibitors to combat HCV infection, in
particular of genotype 3.Methods
Extraction of RNA and cDNA synthesis
Blood samples were collected from different hospitals,
already involved in work of HCV diagnostic services (Punjab
Institute of Nuclear Medicine, Faisalabad Pakistan and
Table 3 Secondary structure analysis of His6-NS3 and
NS5A-T-His6 by FT-IR, CD spectroscopy and
homology modeling
Protein Method α-helix (%) β-sheet (%)
NS3 FT-IR1 25.7 34.6
CD2 24.4 46
CD3 11 37.6
Homology model4 25 30
NS5A-T FT-IR1 29 28
CD2 9.1 32.7
CD3 18 37
1Bands contributing (FT-IR spectra) to each type of secondary structure are
indentified in Figure 7B and 7D respectively. Bands assignments for
interpretation of spectra were made on the basis of previous measurements
[48,58]. 2CD spectra shown in Figure 5 were analyzed using protein
concentration independent method at web based server http://perry.freeshell.
org/raussens.html [52]. 3CD spectra were analyzed using DichroWeb server at
http://dichroweb.cryst.bbk.ac.uk/html/home.shtml [53,54] and program
CONTIN/reference set 3 [55]. 4Secondary structure are estimated from the
homology model of NS3/3a, built using the x-ray structure of NS3/1a
(PDB ID: 3o8b) as a template [49].



















Nucleotides shown as italicized represent the respective restriction sites used
for cloning purposes whereas underlined nucleotides sequence encode for
oligohistidine tag, incorporated into genes of interest for downstream
purification processes.
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Pakistan). Informed consent was taken from every
donor and approval of institutional ethical committee
was obtained to conduct such studies. Plasma was
separated from blood samples by centrifuging them and
stored at −20°C until RNA extraction. Total RNA was
extracted from these samples infected with HCV genotype
3a using the Viral RNA extraction kit (MACHERY-
NAGEL, Germany) according to manufacturer’s instruc-
tion. 140 μl of plasma sample was used to extract RNA
and finally eluted using the 60 μl elution buffer supplied
with kit. RNA was quantified using the nanodrop (Thermo
Scientific) and stored at −80°C if needed. cDNA was
synthesized from the extracted RNA using the primers for
NS3 and NS5A (NS3-cDNA and NS5A-cDNA, Table 4)
with RevertAid™ H Minus First strand cDNA synthesis
kit (Fermentas, Germany) according to manufacturer’s
recommendations.
PCR amplification and construction of expression constructs
Nucleotide sequences of NS3A and NS5A of a number
of isolates of HCV genotype 3a were retrieved from the
European Hepatitis C Virus database (http://euhcvdb.
ibcp.fr/euHCVdb/) and primers were designed from the
consensus sequences of NS3, NS5A and NS5A-T (lacking
N-terminal 31 amino acids), using vector NTI software
(Invitrogen). Nucleotide coding regions for NS3, NS5A
and NS5A-T were amplified from respective cDNA (see
section “Extraction of RNA and cDNA synthesis”) through
gradient polymerase chain reaction (PCR) using NS3-F/R,
NS5A-F/R and NS5A-T-F/R, respectively (Table 4) and
relevant restriction sites/nucleotides encoding for 6 ×His
tag were also incorporated. Each reaction mixture of 50 μlcontains 5 μl of cDNA, 0.2 mM dNTPs, 2 mM MgSO4,
0.5 μM of each forward and reverse primer, 1.25 U of
Pfu DNA Polymerase and 1X Pfu buffer (200 mM Tris–
HCl pH 8.8, 100 mM (NH4)2SO4, 100 mM KCl, 1% Triton
X-100, 1 mg/mL BSA (Fermentas, Germany).
The procedures for cloning were based on standard
methods [51] and protocols recommended by the suppliers.
Purified PCR products corresponding to NS3, NS5A and
NS5A-T were restricted using the restriction enzymes
BamHI/HindIII, NdeI/HindIII and NdeI/HindIII, respect-
ively and ligated into pET11a vector that was restricted
using same restriction enzymes. The resulting constructs
were named as pET11a-His6-NS3, pET11a-NS5A-His6
and pET11a-NS5A-T-His6. The identity of plasmids was
confirmed by nucleotide sequencing. All genetic ma-
nipulation was performed in Escherichia coli strain XL1-
Blue (Stratagene, USA). Nucleotide sequences of NS3 and
NS5A were deposited in GenBank NCBI under accession
numbers JQ676838 and JQ676840, respectively.
Expression of NS3, NS5A and NS5A-T in E. coli
For initial expression trials, pET11a-His6-NS3, pET11a-
NS5A-His6 and pET11a-NS5A-T-His6 were transformed
into the E. coli strain BL21(DE3) cells and were grown at
37°C in a 50 mL of LB media supplemented with
100 μg/mL of ampicillin until OD600 reaches 0.5-0.6.
The cells were then induced with 1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) and were grown for
additional three hours. E. coli cells expressing His6-NS3,
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fugation at 5000 rpm using the Beckman centrifuge
and resuspended in lysis buffers, 25 mM HEPES [4-(2-
hydroxyethyl)-1-piperazineethanesulfonic Acid] pH 7.6
containing 20% glycerol, 0.5 M NaCl, 2.5 mM β-
mercaptoethanol, 0.2% n-dodecyl-β-D-maltopyranoside
and 100 mM Tris–HCl pH 8.0 containing 0.5% triton;
200 mM NaCl; 10 mM β-Mercaptoethanol and 10%
glycerol, respectively. Before sonication, in case of
NS5A cell resuspensions were supplemented with few
μg of DNase, RNase and 1-tablet of EDTA-free pro-
tease cocktail inhibitor (Roche, Germany). Following
disruption of cells by sonication, soluble fraction was
separated from insoluble portion by spinning at 12000 × g
for 30 min. The pellet representing the insoluble fraction
was dissolved in respective lysis buffer and equal volume
of both soluble and insoluble fractions were analyzed
on SDS-polyacrylamide gel.
To optimize the inducer concentration for expression
of His6-NS3 and His6-NS5A-T, various quantities of
IPTG 0.1 mM, 0.25 mM, 0.5 mM, 0.75 mM and 1 mM
IPTG were used in expression experiments and analyses
were performed as described before. To enhance solubility
and yield of His6-NS3 and His6-NS5A-T, following
induction of cultures using 1 mM and 0.5 mM IPTG
respectively, optimization of temperature was carried
out at 32°C, 25°C and 14°C. For 32°C, 25°C and 14°C
post-induction time was kept 4 and 12 hours respectively.
Expressed proteins were analyzed by SDS-PAGE.Purification of NS3
To estimate yield of purified His6-NS3 at various post-
induction temperatures 32°C, 25°C and 14°C, 1.5 L ex-
pression culture was set up at each temperature. Before
IPTG induction, culture media was supplemented with
100 μM of ZnCl2.
For purification, the ÄKTA explorer platform (GE
Healthcare) was used. All purification procedures were
performed at 4°C.The pellet was resuspended in 25 mL
lysis buffer (25 mM HEPES [4-(2-hydroxyethyl)-1-pi-
perazineethanesulfonic Acid] pH 7.6 containing 20%
glycerol, 0.5 M NaCl, 2.5 mM β-mercaptoethanol, 0.2%
n-dodecyl-β-D-maltopyranoside. The cells were lysed
using cell disrupter at 17 Kpsi (Constant Systmes, Ltd)
and lysate was centrifuged for 50 min at 12000 × g. The
pellet was discarded and supernatant was loaded on
the chelating sepharose FastFlow gel charged with
Nickel (GE healthcare) pre-equilibrated with lysis buf-
fer. To remove non-specific loosely bound protein from
Nickel-sepharose matrix, a step gradient with increasing
concentration of imidazole (5 mM and 50 mM) in lysis
buffer was used. His6-NS3 was then eluted using the
lysis buffer except containing 250 mM imidazole.The peak protein fractions were pooled and applied on
PD-10 desalting columns (GE Healthcare) pre-equilibrated
with buffer (25 mM HEPES pH 7.6 containing 20%
glycerol, 0.2 M NaCl, 10 mM β-mercaptoethanol, 0.1%
n-dodecyl-β-D-maltopyranoside) to remove the excess
of imidazole. Concentration of purified His6-NS3 was
measured using nanodrop and Pierce™ 660 nm protein
assay (Thermo Scientific). The purified protein was stored
at −80°C in small portions. Purity of the purified protein
was judged by SDS-PAGE.Purification of NS5A-T
For purification of His6-NS5A-T, cultures were grown
exactly as explained for His6-NS3 except protein expres-
sion was induced using 0.5 mM IPTG. Cells containing
over-expressed His6-NS5A-T were lysed and processed as
described before for His6-NS3. Soluble fraction from lysate
was loaded on sepharose-Nickel column pre-equilibrated
with lysis buffer (100 mM Tris–HCl pH 8.0 containing
0.1% triton, 200 mM NaCl, 10 mM β-Mercaptoethanol
and 10% glycerol). The column was washed with 10 and 3
column volume lysis buffer containing 10 and 60 mM
imidazole, respectively. The protein was eluted using lysis
buffer containing 300 mM imidazole. Peak fractions were
pooled and concentrated using 30 kDa cutoff Vivaspin
column (Sartorius, Germany). The concentrated protein
sample was then loaded onto superdex 200 gel filtration
column pre-equilibrated with the buffer (25 mM HEPES
pH 7.5 containing 150 mM NaCl, 2 mM DTT and 10%
glycerol) and let the sample pass through the column
with a flow rate of 0.5 mL/min. The fractions with high UV
absorption were collected and analyzed by SDS-PAGE.Circular dichroism spectroscopy analysis of NS3
and NS5A-T
Structural analysis of His6-NS3 produced at 32°C, 25°C
and 14°C were performed using CD spectroscopy. Mea-
surements were carried out using J-810, Jascon spectro-
plolarimeter at 25°C with constant nitrogen flushing.
Samples (300 μl) containing the purified His6-NS3 and
His6-NS5A-T at a concentration of 0.02 mg/mL (in 10 mM
potassium phosphate pH 7.4 buffer supplemented with
20% glycerol, 0.1% n-octyl-β-D-glycopyranosid) and
0.05 mg/mL (in 10 mM potassium phosphate pH 7.4
buffer) respectively, were added into a Hellma quartz
cuvette of 1 mm path length and scanned between 185
and 260 nm, averaging at least 10 accumulations. Similarly,
blank samples containing 10 mM phosphate buffer pH 7.4
supplemented with 20% glycerol, 0.1% n-octyl-β-D-gly-
copyranosid or 10 mM phosphate buffer pH 7.4 were
scanned. Spectra were recorded at a speed of 1 nm/15 sec,
sensitivity 50 mdeg, bandwidth 0.5 nm, resolution 1 nm
and response time 15 sec.
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independent method at web based server http://perry.
freeshell.org/raussens.html [52] and DichroWeb server
at http://dichroweb.cryst.bbk.ac.uk/html/home.shtml
[53,54] and program CONTIN/reference set 3 [55].
Activity measurements of NS3
The protease activity was measured with fluorescence
resonance energy transfer assay (FRET) using the dep-
sipeptide substrate Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-
Abu-ψ-[COO]-Ala-Ser-Lys(DABCYL)-NH2 (AnaSpec, San
Jose, CA, USA). NS3 Protease cleave this substrate
resulting in production of fluorescence which can be
measured continuously on a fluorescence plate reader
(Fluoroskan, Ascent Labsystems, Sweden) with excitation
and emission wavelengths at 355 and 510 nm, respectively.
The cofactor for NS3 protease activity is a synthetic
peptide “KKGSVVIVGRIVLSGK” which is the central
part of HCV NS4A. For activity measurement, purified
His6-NS3 was diluted to 1 nM with the assay buffer
(50 mM HEPES pH 7.5 containing 10 mM DTT, 40%
glycerol and 0.1 or 0.4% n-octyl-β-D-glycopyranoside),
pre-incubated for 10 min at 30°C with 25 μM NS4A-
peptide (dissolved in dimethyl sulfoxide). The assay
buffer with 0.1 or 0.4% OPG was used in order to see
the effect of detergent concentration on activity of NS3.
The reaction was started by adding 10 μl of depsipeptide
substrate in 2 fold dilution with highest concentration
of 4 μM in a microtitre plate. The last well in microtitre
plate was used as control containing no substrate in it.
Corrections for inner filter effect of substrate were also
performed [56]. Kinetic properties of enzyme (Km, Kcat and
Kcat/Km) were measured by fitting the Michaelis-Menten
equation by non-linear regression using the GraFit soft-
ware (Erithacus Software, Staines, MX, UK).
FT-IR analysis of NS3 and NS5A-T
For infrared spectroscopy, purified His6-NS3 and His6-
NS5A-T in 10 mM potassium phosphate buffer pH 7.4
supplemented with 0.1% n-dodecyl-β-D-maltopyranoside
and 10 mM potassium phosphate buffer pH 7.4, respect-
ively, were concentrated to ~ 5–6 mg/mL. A small amount
(~ 15 μl) of sample was dried on platinum ATR platform
(diamond crystal) to form a hydrated film and then spectra
obtained using Bruker FT-IR spectrometer as described
[57]. Briefly FT-IR spectra from 4000 to 500 cm-1 were
collected in absorbance mode at 1 nm resolution, 256
scans coaddition and Blackman-Harris-3-term apodiza-
tion. Similarly, spectra was recorded for buffer alone
and subtracted from protein spectra to eliminate bending
vibration of H2O that gives absorption band at around
1645 cm-1 in the amide I region. Subtracted protein
spectra were manipulated by adjusting the subtraction
factor until a flat baseline was obtained in the regionbetween 2000–1770 cm-1. Where necessary, subtraction
of residual vapour absorption was also performed.
For secondary structure analysis, second derivative of
spectra corresponding to amide I region (1700–1600 cm-1)
was obtained using the Origin software version 7.0
(OriginLab Corporation, USA) following Savitzky-Golay
method using the parameters 3rd grade polynomial, point
to left/right : 2 and five smoothing points. Before perform-
ing second derivative analyses, spectra were smoothened
using 2 adjacent points. Decomposition of the spectra into
individual bands in the amide I region was performed
by non-linear peak fitting using Galactic PeakSolve™
software (version 1.05). Band assignments for interpret-
ation of spectra were done on the basis of previous
measurements [48,58].
Homology modeling
The 3D structure of HCV-3a NS3 protein was predicted
through homology modeling, using the SWISS-MODEL
Workspace [50,59]. 629 amino acids (3–631) were mod-
eled using the x-ray structure of HCV-1a NS3 protein as
a template (PDB ID: 3o8b, sequence identity 83%). The
homology model was further idealized using the CCP4
program suite [60,61]. The final model was validated
using the NIH MBI Laboratory for Structural Genomics
and Proteomics Structural Analysis and Verification Server
that allow use of five programs (Procheck, What_Check,
ERRAT,Verify_3D, and Prove) to analyze the stereochemical
parameters and quality of the model [62-66].
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